ArticleFEBS open bio2023
An open chat with… Sandro Sonnino.
Article in FEBS open bio, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
- Serving the scientific community: FEBS Open Bio in 2024.FEBS open bio · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sandro Sonnino is one of the founding members of the Editorial Board of FEBS Open Bio, having joined in 2011. He is also a member of the Editorial Board of FEBS Letters and is the Editor-in-Chief of Glycoconjugate Journal. He is full professor of biochemistry in the School of Medicine at the University of Milan, where he was also formerly coordinator of the Interdisciplinary Laboratory of Advanced Technology (LITA) and Director of the Department of Medical Chemistry, Biochemistry, and Biotechnology. His research is focused on the metabolism and biochemical properties of gangliosides and glycosphingolipids, and their role in cell signaling and the nervous system. He is a guest editor of this special "In the Limelight" issue on glycosphingolipids in disease, which features multiple Reviews and an original research article related to this field. In this interview, Sandro Sonnino discusses the ongoing importance of research on glycosphingolipids and his personal career journey.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.